Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CorMedix Inc. (CRMD)

CorMedix reaffirms 2026 revenue guidance of $325 million to $345 million

Neutral Impact 3 of 5 guidance Written later

CorMedix said unaudited cash and cash equivalents were about $355 million as of September 30, 2026, and reaffirmed its full-year 2026 total revenue guidance. The company also said CMS's final rule sets a $8.32 per session DefenCath Add-on for the first quarter of 2027, and it expects the 2027 average Add-on rate to exceed twice the current $2.37 rate.

Key points

  • Unaudited cash and cash equivalents of about $355 million as of September 30, 2026
  • 2026 total revenue guidance of $325 million to $345 million reaffirmed, unchanged from August 2026
  • CMS set a DefenCath post-TDAPA Add-on of $8.32 per dialysis session for Q1 2027, versus $2.37 in effect for Q3 and Q4 2026
  • Company expects the Add-on to decline in Q2 2027 versus Q1, then rise in Q3 and/or Q4 2027; conference call set for November 12, 2026

The filing

CompanyCorMedix Inc. (CRMD)
Form8-K, current report
Filed with the SECNov 2, 2026, 7:39 AM ET
Accession number0001213900-26-114665

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.